Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.8
(-1.36%)
EUR 5.8
(-1.36%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 5.29 Million EUR | 498.19% |
| 2022 | 885 Thousand EUR | -92.8% |
| 2021 | 12.28 Million EUR | 45.5% |
| 2020 | 8.44 Million EUR | -36.0% |
| 2019 | 13.19 Million EUR | 40.97% |
| 2018 | 9.36 Million EUR | 37.64% |
| 2017 | 6.8 Million EUR | 172.91% |
| 2016 | 2.49 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 1.67 Million EUR | 13.19% |
| 2023 Q3 | 1.51 Million EUR | -9.74% |
| 2023 Q1 | 1.47 Million EUR | 67.01% |
| 2023 FY | 5.29 Million EUR | 498.19% |
| 2023 Q4 | 1.75 Million EUR | 15.96% |
| 2022 Q1 | 6.86 Million EUR | -44.17% |
| 2022 Q2 | 66 Thousand EUR | -99.04% |
| 2022 Q3 | 747 Thousand EUR | 1031.82% |
| 2022 FY | 885 Thousand EUR | -92.8% |
| 2022 Q4 | 885 Thousand EUR | 18.47% |
| 2021 Q1 | 8.3 Million EUR | -1.18% |
| 2021 FY | 12.28 Million EUR | 45.5% |
| 2021 Q4 | 12.28 Million EUR | 40.86% |
| 2021 Q3 | 8.72 Million EUR | 6610.77% |
| 2021 Q2 | 130 Thousand EUR | -98.43% |
| 2020 Q4 | 8.4 Million EUR | 0.0% |
| 2020 Q3 | 8.4 Million EUR | -0.05% |
| 2020 Q1 | 26.83 Million EUR | 104.06% |
| 2020 FY | 8.44 Million EUR | -36.0% |
| 2020 Q2 | 8.4 Million EUR | -68.69% |
| 2019 Q3 | 13.15 Million EUR | 0.0% |
| 2019 Q4 | 13.15 Million EUR | 0.0% |
| 2019 FY | 13.19 Million EUR | 40.97% |
| 2019 Q1 | - EUR | 0.0% |
| 2018 FY | 9.36 Million EUR | 37.64% |
| 2017 FY | 6.8 Million EUR | 172.91% |
| 2016 FY | 2.49 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -56.165% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 90.455% |
| Adocia SA | 13.08 Million EUR | 59.551% |
| Aelis Farma SA | 4.03 Million EUR | -31.105% |
| Biophytis S.A. | 8.27 Million EUR | 35.985% |
| Advicenne S.A. | 17.42 Million EUR | 69.618% |
| genOway Société anonyme | 7.23 Million EUR | 26.812% |
| IntegraGen SA | 1.12 Million EUR | -370.689% |
| Medesis Pharma S.A. | 1.2 Million EUR | -341.167% |
| Neovacs S.A. | 650 Thousand EUR | -714.462% |
| NFL Biosciences SA | 62.17 Thousand EUR | -8414.813% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -21.519% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -94.859% |
| Sensorion SA | 2.86 Million EUR | -84.538% |
| Theranexus Société Anonyme | 3.64 Million EUR | -45.319% |
| TME Pharma N.V. | 1.16 Million EUR | -354.031% |
| Valbiotis SA | 6.87 Million EUR | 23.03% |
| TheraVet SA | 1.15 Million EUR | -356.432% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 41.165% |
| argenx SE | 18.1 Million EUR | 70.76% |
| BioSenic S.A. | 28.16 Million EUR | 81.201% |
| Celyad Oncology SA | 902 Thousand EUR | -486.918% |
| DBV Technologies S.A. | 13.01 Million USD | 59.335% |
| Galapagos NV | 9.59 Million EUR | 44.831% |
| Genfit S.A. | 70.17 Million EUR | 92.456% |
| GeNeuro SA | 7.73 Million EUR | 31.583% |
| Innate Pharma S.A. | 39.89 Million EUR | 86.73% |
| Inventiva S.A. | 37.4 Million EUR | 85.848% |
| MaaT Pharma SA | 14.07 Million EUR | 62.387% |
| MedinCell S.A. | 58.96 Million EUR | 91.021% |
| Nanobiotix S.A. | 50.56 Million EUR | 89.53% |
| Onward Medical N.V. | 16.87 Million EUR | 68.626% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 61.322% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 88.441% |
| Oxurion NV | 12.33 Million EUR | 57.078% |
| Pharming Group N.V. | 155.29 Million EUR | 96.591% |
| Poxel S.A. | 46.9 Million EUR | 88.712% |
| GenSight Biologics S.A. | 18.42 Million EUR | 71.272% |
| Transgene SA | 1.25 Million EUR | -321.161% |
| Financière de Tubize SA | 79.2 Million EUR | 93.316% |
| UCB SA | 3.03 Billion EUR | 99.826% |
| Valneva SE | 208.81 Million EUR | 97.465% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -13831.579% |